Introduction
The early diagnosis of acute coronary syndrome (ACS) in patients with chest pain remains a challenge for internists even in the era of troponins, especially in the case of an atypical clinical presentation and absence of typical electrocardiographic (ECG) signs.
Heart -type fatty acid-binding protein (hFABP) is an early marker of myocardial damage and necrosis. It reaches the diagnostic concentration in blood just within 1 to 2 hours after the onset of clinical symptoms. 1 Several studies have shown high efficacy of the hFABP evaluation in the early diagnosis of ACS; it has a higher sensitivity than cardiac troponins (cTns) and creatine kinase-MB (CK -MB) and higher specificity than myoglobin. 2-4 However, recent meta -analyses have provided controversial results. 5 -6 Therefore, the role of hFABP in the diagnostic algorithm for ACS remains unclear.
A quantitative assessment of hFABP in early stages of ACS with an enzyme -linked immunosorbent assay is rather complicated, because it requires special laboratory conditions and is time consuming. Therefore, a qualitative bedside hFABP test based on the immunochromatographic method seems to be more practical.
7 In Russia, 2 qualitative bedside hFABP tests have been approved for use and are available on the market. CardioFABP (Biotest, Russia) is a one -step in--vitro express test for evaluating hFABP levels in whole venous blood, with a diagnostic threshold of 10 ng/ml. This test was examined in more than 3500 patients with ACS included in a noncommercial multicenter GIANT trial. The results showed its high sensitivity (66%-100%), depending on the time since onset of clinical symptoms, and satisfactory specificity (67%-100%) in the early (33.2%); hypercholesterolemia, in 43 (21.6%); history of stroke or transient ischemic attack, in 23 (11.6%); chronic lung diseases, in 15 (7.5%); chronic renal diseases, in 28 (14.1%); and anemia, in 14 (7.0%).
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In 66 patients (33.2%), biomarkers were evaluated between 1 and 3 hours since the onset of clinical symptoms; in 68 patients (34.2%), between 3 and 6 hours; and in 65 patients (32.7%), between 6 and 24 hours. ECG on admission revealed ST -segment elevation in 88 patients (44.2%); ST -segment depression, in 49 (24.6%); left bundle branch block or artificial ventricular pace, in 11 (5.5%); and new Q wave without ST -segment deviations, in 7 patients (3.6%). In 44 patients (22.1%), no or nonspecific changes were observed on ECG.
The final diagnosis of MI was confirmed in 111 patients (55.8%); unstable angina, in 69 (34.7%); other heart diseases, in 8 (4%). Clinical symptoms due to noncardiac disorders were reported in 11 patients (5.5%). During hospitalization, echocardiography was performed in 187 patients (94%), and coronary angiography, in 130 (65.3%). Death on admission was reported in 14 patients (7%); in 9 cases, the diagnosis of MI was confirmed on autopsy.
The diagnostic performance of the hFABP tests and troponin assays is presented in TABLE 1. CardioFABP had overall higher sensitivity compared with both cTnI (P <0.001) and hs -TnI (P <0.001) assays. The difference was observed only in patients with ACS with ST -segment elevation. There was no significant difference in sensitivity between hFABP tests and both troponin assays in patients with ACS without ST -segment elevation. The overall specificity of CARD -INFO was superior to cTnI (P = 0.02), and lower in the case of CardioFABP versus hs -TnI (P <0.001). The difference was significant only in patients with ACS without ST -segment elevation.
During the period between 1 and 3 hours, CardioFABP showed higher sensitivity compared with both cTnI (P <0.001) and hs -TnI (P <0.001) assays on admission. In the period from 3 to 6 hours, it was higher only in comparison with cTnI (P = 0.02), and there were no differences in sensitivity between hFABP tests and cTnI assays after 6 hours since the onset of chest pain.
Both hFABP tests revealed similar diagnostic accuracy to the hs -TnI assay, and it was higher compared with the cTnI assay (P = 0.03 and P = 0.05, respectively).
The CARD -INFO test had the highest PPV compared with the cTnI assay (P = 0.03), while the CardioFABP test demonstrated better NPV compared both with cTnI (P = 0.005) and hs -TnI (P = 0.047) assays on admission. There were no other significant differences between hFABP and troponin tests.
Discussion
This study evaluated the diagnostic value of 2 qualitative bedside hFABP tests in comparison with cTnI and hs -TnI assays in using the TnI assay (Immunolite 2000 Troponin I, Siemens, Germany), with a diagnostic threshold (99th percentile) of 0.5 ng/ml. Hs -TnI (Pathfast cTnI, Mitsubishi Chemical, Japan) was also measured serially on admission and at 3 to 6 hours. The diagnostic cutoff value for the hs--TnI assay was 0.02 ng/ml. Patients were diagnosed and treated according to the guidelines of the European Society of Cardiology.
The final diagnosis was established on the basis of the Third Universal Definition of Myocardial Infarction (2012) . MI was diagnosed when at least a single value of cTnI (or hs -TnI) above the 99th percentile was observed in a clinical setting, consistent with myocardial ischemia. Unstable angina was diagnosed based on symptoms accompanied by dynamic ECG changes, signs of ischemia on functional tests, or new coronary angiographic lesions. The final diagnosis was confirmed by an independent cardiologist on the basis of all available clinical, laboratory, and ECG data, coronary angiography, echocardiography, and cardiac exercise test.
To evaluate the diagnostic value of the hFABP tests, we constructed two -by -two tables with the number of true positive, false positive, true negative, and false negative test results, with MI as an outcome. We calculated sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) with 95% CIs, and compared the values between hFABP tests and troponin assays. The first measurement of troponin levels (on admission) was used only to determine the diagnostic efficacy. Subgroup analyses were performed to assess whether the diagnostic values differed according to time since the onset of chest pain (1-3 h, from 3 to 6 h, and >6 h) and type of ACS (with or without ST -segment elevation or a left bundle branch block).
The statistical analysis was performed with Statistical Package for the Social Sciences, version 22.0 (SPSS Inc., United States). The baseline characteristics were assessed with the parametric t test and nonparametric Mann-Whitney test for continuous variables, and with the χ 2 test for categorical variables (with the Yates correction in case of small data). Two -tailed P values of less than 0.05 were considered significant.
The study was conducted in accordance with the standards of Good Clinical Practice and the principles of the Declaration of Helsinki. The protocol was approved by the ethics committee of Pirogov Russian National Research Medical University. All participants provided written informed consent.
Results Among the 199 enrolled patients, 63 (31.7%) had previous MI and 62 (31.2%), angina pectoris; 168 patients (84.4%) had hypertension; 75 (37.7%), obesity; 36 (18.1%), type 2 diabetes; 39 (19.6%), atrial fibrillation; and 37 (18.6%), symptoms of chronic heart failure. Active smoking was reported in 66 patients patients with suspected ACS. The CardioFABP test showed higher sensitivity, especially during the first 3 hours since MI onset, compared with cTnI and hs -TnI assays, but it had lower specificity than the hs -TnI assay. The CARD -INFO test showed better sensitivity during the period from 3 to 6 hours and better overall specificity compared with the cTnI assay; however, it did not show significant differences with the hs -TnI assay for most diagnostic parameters. We believe that both bedside hFABP tests could have diagnostic value, but more clinical evidence is needed to define their role in the early diagnosis of ACS.
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